Welcome to our dedicated page for Genmab SEC filings (Ticker: GMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Genmab A/S (GMAB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer listed on Nasdaq. Genmab files annual reports on Form 20‑F and furnishes current reports on Form 6‑K under the Securities Exchange Act of 1934. These filings cover a wide range of topics, from interim financial results and capital increases to equity awards, articles of association and material company announcements.
Recent Forms 6‑K referenced in the available data include interim reports, company announcements about net sales of partnered products such as DARZALEX, capital increases resulting from employee warrant exercises, grants of restricted stock units and warrants, and disclosures related to the proposed acquisition of Merus N.V. and associated financing. Other 6‑K filings incorporate company announcements on regulatory milestones for EPKINLY (epcoritamab‑bysp), portfolio prioritization decisions and updates on late‑stage clinical programs.
Because Genmab uses its 6‑K reports to furnish key announcements to U.S. investors, these filings can be a primary source for understanding changes in its capital structure, details of tender offers and acquisitions, and the status of important clinical and commercial programs. On Stock Titan, users can review these documents alongside AI‑powered summaries that explain the context and main points of each filing, helping to interpret technical content in forms such as 6‑K and 20‑F.
Investors researching GMAB can use this page to follow how Genmab reports on its antibody platforms, collaborations, late‑stage pipeline, financing arrangements and governance documents over time. The combination of real‑time EDGAR updates and AI‑generated insights is intended to make it easier to navigate lengthy filings and identify information relevant to Genmab’s business and capital markets activity.
Genmab A/S, a Denmark-based biotechnology company, submitted a Form 6-K as a foreign private issuer to the U.S. Securities and Exchange Commission for November 2025. The filing primarily makes Genmab’s updated Articles of Association available to U.S. investors as an exhibit.
The report states that this Form 6-K is incorporated by reference into several existing Genmab registration statements on Form S-8, meaning the updated governance document becomes part of those employee share incentive-related registrations. The filing is signed on behalf of the company by Executive Vice President & Chief Financial Officer Anthony Pagano.
Genmab A/S filed a Form 6-K as a foreign private issuer for November 2025. The filing attaches a company announcement dated November 18, 2025 describing a capital increase in Genmab resulting from the exercise of employee warrants.
The Form 6-K is expressly incorporated by reference into Genmab’s existing Form S-8 registration statements, making this capital increase disclosure part of those employee equity compensation-related registrations.
Genmab Holding II B.V., a wholly owned subsidiary of Genmab A/S, filed Amendment No. 1 to its tender offer to acquire all outstanding common shares of Merus N.V. (MRUS) for $97.00 in cash per share, less any applicable withholding taxes and without interest.
The parties filed HSR premerger notifications on October 28, 2025. As a result, the required 15‑day waiting period will expire at 11:59 p.m., New York City time, on November 12, 2025, unless withdrawn and refiled, shortened by Early Termination, or extended by a Second Request.
The amendment also updates post‑closing governance plans. If Dr. Lundberg resigns as President and CEO of Merus and Merus US, Inc. following the Closing, Genmab plans for the Merus Board to appoint Dr. Jan G.J. van de Winkel as President and CEO. Genmab and the Purchaser have designated Anthony Pagano, Martine J. van Vugt, Ph.D., and Greg Mueller as non‑executive directors and Dr. van de Winkel as executive director, effective upon Closing and, for the non‑executives, subject to adoption of Governance Resolutions at the EGM or a Subsequent EGM.
Genmab Holding II B.V., a wholly owned subsidiary of Genmab A/S, commenced a cash tender offer to purchase all issued and outstanding common shares of Merus N.V. (MRUS) for $97.00 per share, less any applicable withholding taxes and without interest. The offer is made upon the terms and subject to the conditions set forth in the Offer to Purchase dated October 21, 2025, together with the accompanying Letter of Transmittal.
The filing lists related exhibits, including the Offer to Purchase, Letter of Transmittal, a media release announcing commencement, and a Debt Commitment Letter with Morgan Stanley Senior Funding, Inc. A Transaction Agreement among Genmab, the Purchaser, and Merus is referenced. Shareholders who tender and whose shares are accepted would receive cash consideration of $97.00 per share under the offer terms.
Genmab A/S submitted a Form 6-K as a foreign private issuer for October 2025. The filing makes a company announcement, dated October 14, 2025, available as an exhibit, which covers net sales of DARZALEX (daratumumab) for the third quarter of 2025.
The Form 6-K is also deemed incorporated by reference into several existing Genmab registration statements on Form S-8, meaning the information in this report becomes part of those employee equity compensation-related disclosures.
Genmab A/S has filed a Form 6-K to furnish a company announcement stating that it plans to acquire Merus. The announcement highlights that the deal is intended to expand Genmab’s late-stage drug pipeline and accelerate a shift toward a wholly owned product model, meaning Genmab aims to control more of its future medicines rather than relying mainly on partnerships.
The Form 6-K is also designated to be incorporated by reference into several existing Genmab registration statements on Form S-8, so the information in this report becomes part of those employee share incentive-related filings.